Immuneering (NASDAQ:IMRX) Insider Harold Eugene Brakewood Purchases 5,250 Shares

Immuneering Corporation (NASDAQ:IMRX) insider Harold Eugene Brakewood bought 5,250 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was acquired at an average price of $4.76 per share, for a total transaction of $24,990.00. Following the acquisition, the insider directly owned 11,050 shares in the company, valued at $52,598. The trade was a 90.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

Immuneering Stock Performance

IMRX traded down $0.11 during midday trading on Wednesday, reaching $4.67. 500,450 shares of the company were exchanged, compared to its average volume of 3,836,054. The company has a market cap of $301.74 million, a price-to-earnings ratio of -2.62 and a beta of 0.48. Immuneering Corporation has a one year low of $1.10 and a one year high of $10.08. The company’s fifty day moving average price is $6.28 and its 200 day moving average price is $5.83.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, sell-side analysts anticipate that Immuneering Corporation will post -1.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Iridian Asset Management LLC CT bought a new position in Immuneering in the 3rd quarter worth about $1,926,000. Flower City Capital purchased a new stake in shares of Immuneering in the second quarter worth about $108,000. Kingsview Wealth Management LLC bought a new position in shares of Immuneering in the second quarter valued at approximately $47,000. GSA Capital Partners LLP purchased a new position in Immuneering during the third quarter valued at approximately $265,000. Finally, Palumbo Wealth Management LLC bought a new stake in Immuneering during the 3rd quarter worth approximately $343,000. 67.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on IMRX shares. Leerink Partners assumed coverage on shares of Immuneering in a research report on Friday, October 31st. They set an “outperform” rating and a $15.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Wall Street Zen cut Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Mizuho set a $12.00 price objective on shares of Immuneering in a report on Wednesday, October 29th. Finally, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research note on Tuesday, September 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Immuneering has a consensus rating of “Moderate Buy” and a consensus price target of $16.50.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.